ClinicalTrials.gg
CompletedNCT05222490Updated Aug 13, 2024

FeetSee Thermal Images Collection Protocol

An interventional study of Thermal Camera images acquisition - FeetSee and Thermal Camera images acquisition - Reference in Diabetic Foot, sponsored by Diabetis JSC. Completed at 1 site in Lithuania. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-13.

Sponsored by Diabetis JSC · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jul 2021, registered Nov 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
112
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to collect thermal images of diabetic patients' feet to evaluate the performance of Feetsee - foot monitoring device for periodic evaluation of the temperature over the soles of the feet for signs of inflammation.

Read the detailed description

The aim of this study is to collect a database of thermal images of the diabetic persons' feet, and non-diabetic control groups' feet images, which in turn will enable us to build a system based on a mobile thermal camera and a mobile application for possible indication of signs of inflammation in feet. Enrolled participants will undergo a detailed history and physical examination of the foot at the beginning of the procedure day. Then the thermal images of the patient's feet will be taken. Participants will be also asked to take thermal images of their feet according to very well-explained instructions provided by the sponsor. Thermal images using the reference thermal camera will be taken following the Feetsee thermal camera. The images will be unidentified, collected, and stored for the development and performance evaluation of the Feetsee device Algorithm. At the end of the study procedure, participants or their caregivers will receive a short questioner on their experience with using the study device.

02

Conditions studied

  • Diabetic Foot

Browse trials for

03

In context

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

This study's enrollment of 112 is above the median of 60 across 849 interventional studies indexed under Diabetic Foot.

Browse Diabetic Foot studies →

Lead sponsor

Diabetis JSC is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria

Group 1/2: Diabetic with/without ulcers

  1. Male/Female, 18 years or older
  2. Diagnosis of type 1 or type 2 Diabetes Mellitus, confirmed by a family physician or an endocrinologist.
  3. Patient with or without history of previous foot ulcer, confirmed by a family physician or an endocrinologist
  4. For Group 1: Patient with diabetic foot and ulceration diagnosed/confirmed by the study physician on the day of enrollment For Group 2: Patient without ulcers diagnosed/confirmed by the study physician on the day of enrollment
  5. Must be able to read, understand and sign the Form Control: Generally Healthy Non-diabetic
  1. Male/Female, 18 years or older 2. No diabetes mellitus or other diseases that may have signs of polyneuropathy or impaired blood circulation in the foot. 3.No damage to the skin or the soft tissues of the examined feet. 4. Must be able to read, understand and sign the Informed Consent Form

Exclusion Criteria:

  1. Critical ischemia and/or deep ulceration (grades 4 or 5 according to Texas grading system).
  2. Active Infection/Gangrene
  3. Active
  4. disease
  5. History of alcohol or drug abuse
  6. Pregnant women (verbal confirmation or confirmation obtained within current medical records)
  7. Cognitive deficit
  8. End-stage renal disease
  9. History of amputation proximal to the Trans-metatarsal (TM) joint
  10. Other issues that, at the discretion of the investigator, renders the subject ineligible for participation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Diabetic with Ulcers

    Patient with diabetic foot and ulceration diagnosed/confirmed by the study physician on the day of enrollment

    Device: Thermal Camera images acquisition - FeetSee · Device: Thermal Camera images acquisition - Reference

  • Experimental
    Diabetic without Ulcers

    Patient without ulcers diagnosed/confirmed by the study physician on the day of enrollment

    Device: Thermal Camera images acquisition - FeetSee · Device: Thermal Camera images acquisition - Reference

  • Active comparator
    Control

    Generally Healthy Non-diabetic Subjects

    Device: Thermal Camera images acquisition - FeetSee · Device: Thermal Camera images acquisition - Reference

Interventions

  • DeviceThermal Camera images acquisition - FeetSee

    Thermal images will be collected according to the instructions for use of the Feetsee device.

  • DeviceThermal Camera images acquisition - Reference

    After 15 minutes of resting, thermal images from the reference device will be collected according to their manufacturer

06

What researchers measure

Primary outcomes

  1. Estimate of a difference in temperature between two feet per subject

    The primary outcome of this study is collecting of adequate thermal images from study groups' individuals using Feetsee device in order to develop and evaluate its performance to detect a temperature difference between two foot as a potential sign of inflammation and compare the camera performance to the reference camera.

    Time frame: through study completion, on average within of 1 year

Secondary outcomes

  1. To evaluate the usability of FeeSee device by patient and healthcare providers

    The evaluation of Feetsee device usability by patients or their healthcare providers using a a dedicated usability questioner.

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
  • Inlita Santara CTC
    Vilnius, Lithuania
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Feb 2022, 7 months.

Of 104 industry-sponsored interventional studies with no phase under Diabetic Foot, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's 7 months is below that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2021
First posted
Feb 3, 2022
StartActual
Jul 13, 2021
Primary completionActual
Feb 28, 2022
CompletionActual
Feb 28, 2022
Last update
Aug 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05222490
Lead sponsor
Diabetis JSC
Responsible party
Sponsor
First posted
Feb 3, 2022
Start date
Jul 13, 2021
Primary completion
Feb 28, 2022
Completion
Feb 28, 2022
Last update
Aug 13, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion